UNCY Stock Price, Unicycive Therapeutics, . Quote, Chart

Market Summary

USD1.04+0.01

Delayedas of 17 May 2024, 03:02 pm

0.97%

UNCY Stock Price

View Fullscreen

UNCY RSI Chart

UNCY Valuation

Market Cap

38.7M

Price/Earnings (Trailing)

-1.05

Price/Sales (Trailing)

57.38

Price/Free Cashflow

-1.86

UNCY Price/Sales (Trailing)

UNCY Profitability

Return on Equity

151.01%

Return on Assets

-70.5%

Free Cashflow Yield

-53.79%

UNCY Fundamentals

UNCY Revenue

Revenue (TTM)

675.0K

Rev. Growth (Yr)

-100%

UNCY Earnings

Earnings (TTM)

-36.9M

Earnings Growth (Yr)

-43.83%

Earnings Growth (Qtr)

-168.83%

Breaking Down UNCY Revenue

52 Week Range

0.601.82

(Low)(High)

Last 7 days

-4.6%

Last 30 days

-8.0%

Last 90 days

-24.8%

Trailing 12 Months

-26.4%

How does UNCY drawdown profile look like?

UNCY Financial Health

Current Ratio

1.71

UNCY Investor Care

Shares Dilution (1Y)

146.86%

Diluted EPS (TTM)

-1.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	882.0K	813.0K	744.0K	675.0K
2022	0	0	0	951.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Unicycive Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jul 11, 2023	aggarwal gaurav	acquired	-	-	3,470,150	-
Jul 11, 2023	gupta pramod	acquired	-	-	41,845	evp, pharmaceuticals and bd
Jul 11, 2023	gupta shalabh k.	acquired	-	-	104,612	ceo
Jul 11, 2023	jermasek douglas	acquired	-	-	104,612	evp of corporate strategy
Jul 15, 2022	schiller brigitte	acquired	-	-	26,738	-
May 16, 2022	schiller brigitte	bought	12,375	0.825	15,000	-

Which funds bought or sold UNCY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	17,949	48,350	-%
May 15, 2024	Logos Global Management LP	new	-	3,010,860	3,010,860	0.24%
May 15, 2024	Integrated Wealth Concepts LLC	unchanged	-	5,123	13,800	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	13.6	4,729	10,596	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	unchanged	-	9,631	25,944	-%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-51.49	2,677,580	8,644,200	0.49%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	unchanged	-	1,778,030	4,789,550	0.06%
May 15, 2024	BVF INC/IL	added	70.51	3,146,100	4,984,010	0.14%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-0.01	47,813	128,808	-%
May 15, 2024	CITADEL ADVISORS LLC	added	95.92	65,031	95,765	-%

Are Funds Buying or Selling UNCY?

Are funds buying UNCY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own UNCY

No. of Funds

Unveiling Unicycive Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ra capital management, l.p.	9.99%	3,472,106	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	3,475,713	SC 13G/A
Feb 14, 2024	armistice capital, llc	2.73%	976,000	SC 13G/A
Feb 05, 2024	nantahala capital partners limited partnership	6.1%	2,121,753	SC 13G
Jan 22, 2024	logos global management lp	9.9%	3,469,927	SC 13G
Jul 14, 2023	vivo opportunity fund holdings, l.p.	9.99%	59,961,729	SC 13G
Jul 06, 2023	ra capital management, l.p.	9.99%	3,470,689	SC 13G
Jul 06, 2023	biotechnology value fund l p	5.3%	1,856,241	SC 13G
Feb 14, 2023	nantahala capital management, llc	8.0%	1,207,416	SC 13G/A
Feb 14, 2023	armistice capital, llc	6.08%	976,000	SC 13G/A

Recent SEC filings of Unicycive Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 08, 2024	DEFA14A	DEFA14A
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading

Peers (Alternatives to Unicycive Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Unicycive Therapeutics, Inc. News

Latest updates

Unicycive Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Revenue	-	-	-	-	-	675	813	951
Operating Expenses	45.8%	9,204	6,313	5,938	4,322	4,877	5,325	6,505
S&GA Expenses	-100.0%	-	2,080	2,566	2,055	1,847	1,485	1,702
R&D Expenses	60.9%	6,813	4,233	3,372	2,267	3,030	3,840	4,803
Interest Expenses	2.6%	20.00	20.00	18.00	32.00	12.00	3.00	3.00
Net Income	-168.8%	-20,963	-7,798	-4,333	-3,838	-14,575	-5,328	-5,557
Net Income Margin	-20.9%	-54.71*	-45.25*	-37.73*	-36.04*	-32.99*	-18.99*	-
Free Cashflow	-45.6%	-6,462	-4,439	-4,422	-5,514	-3,920	-6,084	-3,563

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	269.1%	52.00	14.00	19.00	23.00	27.00	3.00	10.00	13.00	16.00	19.00	20.00	-	-
Current Assets	285.7%	52.00	13.00	19.00	22.00	26.00	3.00	10.00	13.00	15.00	18.00	20.00	1.00	0.00
Cash Equivalents	404.4%	49.00	10.00	14.00	19.00	24.00	0.00	7.00	11.00	14.00	17.00	18.00	0.00	-
Net PPE	-11.5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Liabilities	70.3%	31.00	18.00	16.00	16.00	17.00	3.00	6.00	3.00	3.00	2.00	1.00	5.00	3.00
Current Liabilities	72.7%	30.00	18.00	15.00	15.00	16.00	3.00	6.00	3.00	2.00	2.00	1.00	5.00	3.00
Shareholder's Equity	-542.1%	-24.46	-3.81	3.00	-	-15.08	-0.47	5.00	10.00	13.00	16.00	19.00	-	-
Retained Earnings	-32.6%	-85.50	-64.50	-56.74	-52.41	-48.57	-34.00	-28.67	-23.11	-19.48	-15.94	-13.19	-7.99	-5.92
Additional Paid-In Capital	0.5%	61.00	61.00	60.00	33.00	33.00	34.00	33.00	33.00	33.00	32.00	32.00	4.00	3.00
Shares Outstanding	0.0%	35.00	35.00	35.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	14.00	9.00	9.00
Float	-	-	-	-	20.00	-	-	-	12.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-45.4%	-6,456	-4,439	-4,422	-5,502	-3,920	-6,084	-3,563	-3,047	-2,957	-1,403	-3,474	-217	-673	-	-	-
Share Based Compensation	-5.1%	522	550	929	144	144	197	266	294	290	231	239	294	202	71.00	71.00	60.00
Cashflow From Investing	-Infinity%	-6.00	-	-	-12.00	-	-	-	-	-2.00	-	-	-	-	-	-	-
Cashflow From Financing	22388.3%	45,691	-205	-51.00	-	27,797	-	-	-	-	-	21,484	71.00	820	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

UNCY Income Statement

2024-03-31

Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Licensing revenues:		$ 675
Operating expenses:
Research and development	6,813	3,030
General and administrative	2,391	1,847
Total operating expenses	9,204	4,877
Loss from operations	(9,204)	(4,202)
Other income (expenses):
Interest income	69	14
Interest expense	(20)	(12)
Change in fair value of warrant liability	(11,808)	(10,375)
Total other income (expenses)	(11,759)	(10,373)
Net loss	(20,963)	(14,575)
Dividend to preferred stockholders	(208)	(192)
Net loss attributable to common stockholders	$ (21,171)	$ (14,767)
Net loss per share attributable to common stockholders, basic (in Dollars per share)	$ (0.61)	$ (0.97)
Weighted-average shares outstanding used in computing net loss per share, basic (in Shares)	34,912,692	15,232,406
Series A-1 preferred stock
Other income (expenses):
Dividend to preferred stockholders		$ (192)

UNCY Balance Sheet

2024-03-31

Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 48,930	$ 9,701
Prepaid expenses and other current assets	2,746	3,698
Total current assets	51,676	13,399
Right of use asset, net	686	766
Property, plant and equipment, net	23	26
Total assets	52,385	14,191
Current liabilities:
Accounts payable	1,240	839
Accrued liabilities	3,550	3,234
Dividends payable	208
Warrant liability	24,941	13,134
Operating lease liability - current	343	327
Total current liabilities	30,282	17,534
Operating lease liability – long term	372	466
Total liabilities	30,654	18,000
Commitments and contingencies (Note 8)
Stockholders’ deficit:
Preferred stock value
Common stock, $0.001 par value per share – 200,000,000 shares authorized at December 31, 2023 and March 31, 2024; 34,756,049 and 37,606,630 shares issued and outstanding at December 31, 2023 and March 31, 2024, respectively	37	35
Additional paid-in capital	61,011	60,697
Accumulated deficit	(85,504)	(64,541)
Total stockholders’ deficit	(24,456)	(3,809)
Total liabilities and stockholders’ deficit	52,385	14,191
Series B-1 preferred stock
Mezzanine equity:
Series B-1 preferred stock, $0.001 par value per share – zero shares authorized at December 31, 2023, and 50,000 shares authorized at March 31, 2024; zero shares outstanding at December 31, 2023, and 50,000 shares outstanding at March 31, 2024	46,187
Series A-2 preferred stock
Stockholders’ deficit:
Preferred stock value

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

CEO	Dr. Shalabh K. Gupta M.D., MPA
WEBSITE	https://unicycive.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Unicycive Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Unicycive Therapeutics, Inc.? What does UNCY stand for in stocks?

UNCY is the stock ticker symbol of Unicycive Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Unicycive Therapeutics, Inc. (UNCY)?

As of Thu May 16 2024, market cap of Unicycive Therapeutics, Inc. is 38.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UNCY stock?

You can check UNCY's fair value in chart for subscribers.

What is the fair value of UNCY stock?

You can check UNCY's fair value in chart for subscribers. The fair value of Unicycive Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Unicycive Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for UNCY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Unicycive Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether UNCY is over valued or under valued. Whether Unicycive Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Unicycive Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UNCY.

What is Unicycive Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, UNCY's PE ratio (Price to Earnings) is -1.05 and Price to Sales (PS) ratio is 57.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UNCY PE ratio will change depending on the future growth rate expectations of investors.